Cargando…
Limited Durability of Viral Control following Treated Acute HIV Infection
BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal fol...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524377/ https://www.ncbi.nlm.nih.gov/pubmed/15526059 http://dx.doi.org/10.1371/journal.pmed.0010036 |
_version_ | 1782121899453579264 |
---|---|
author | Kaufmann, Daniel E Lichterfeld, Mathias Altfeld, Marcus Addo, Marylyn M Johnston, Mary N Lee, Paul K Wagner, Bradford S Kalife, Elizabeth T Strick, Daryld Rosenberg, Eric S Walker, Bruce D |
author_facet | Kaufmann, Daniel E Lichterfeld, Mathias Altfeld, Marcus Addo, Marylyn M Johnston, Mary N Lee, Paul K Wagner, Bradford S Kalife, Elizabeth T Strick, Daryld Rosenberg, Eric S Walker, Bruce D |
author_sort | Kaufmann, Daniel E |
collection | PubMed |
description | BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. METHODS AND FINDINGS: Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. CONCLUSIONS: These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve. |
format | Text |
id | pubmed-524377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-5243772004-11-02 Limited Durability of Viral Control following Treated Acute HIV Infection Kaufmann, Daniel E Lichterfeld, Mathias Altfeld, Marcus Addo, Marylyn M Johnston, Mary N Lee, Paul K Wagner, Bradford S Kalife, Elizabeth T Strick, Daryld Rosenberg, Eric S Walker, Bruce D PLoS Med Research Article BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. METHODS AND FINDINGS: Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. CONCLUSIONS: These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve. Public Library of Science 2004-11 2004-10-26 /pmc/articles/PMC524377/ /pubmed/15526059 http://dx.doi.org/10.1371/journal.pmed.0010036 Text en Copyright: © 2004 Kaufmann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kaufmann, Daniel E Lichterfeld, Mathias Altfeld, Marcus Addo, Marylyn M Johnston, Mary N Lee, Paul K Wagner, Bradford S Kalife, Elizabeth T Strick, Daryld Rosenberg, Eric S Walker, Bruce D Limited Durability of Viral Control following Treated Acute HIV Infection |
title | Limited Durability of Viral Control following Treated Acute HIV Infection |
title_full | Limited Durability of Viral Control following Treated Acute HIV Infection |
title_fullStr | Limited Durability of Viral Control following Treated Acute HIV Infection |
title_full_unstemmed | Limited Durability of Viral Control following Treated Acute HIV Infection |
title_short | Limited Durability of Viral Control following Treated Acute HIV Infection |
title_sort | limited durability of viral control following treated acute hiv infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524377/ https://www.ncbi.nlm.nih.gov/pubmed/15526059 http://dx.doi.org/10.1371/journal.pmed.0010036 |
work_keys_str_mv | AT kaufmanndaniele limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT lichterfeldmathias limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT altfeldmarcus limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT addomarylynm limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT johnstonmaryn limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT leepaulk limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT wagnerbradfords limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT kalifeelizabetht limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT strickdaryld limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT rosenbergerics limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection AT walkerbruced limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection |